CEO exercised or converted 588 TECH derivative securities | OQRO Insider tradesWhy it stands out
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Aug 15, 2026
- Reporting period
- Not applicable
- Filed with the SEC
- Aug 18, 2026
CEOOption exercise
Context
- Classification
option exercise
Code M — exercise or conversion of a derivative security
- Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0000914190-26-000122
Added to OQROOct 2, 2026, 12:27 PM UTC Data qualityVerified: identifiers matched exactly Reporting personKim Kelderman RelationshipDirector, Officer Officer titleChief Executive Officer SecurityPerformance Restricted Stock Units TableDerivative (Table II) Transaction dateAug 15, 2026 Acquired / disposedDisposed (D) Footnotes from the filing
- Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- On 8/15/2026, the Board of Directors authorized discretionary vesting for 588 performance RSUs. The remainder of the performance RSUs were forfeited.
Around the same time
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.